The Government Pharmaceutical Organization has developed and produced seasonal influenza vaccines for 3 strains, and now the Government Pharmaceutical Organization Tri Fluvax vaccine is currently being submitted for registration approval. The Government Pharmaceutical Organization has begun developing the seasonal influenza vaccine for 4 strains, Tetrafluvax. It is currently entering Phase 1 of clinical research with Professor Emeritus Dr. Punnee Pitisuttithum Leading clinical research. In addition, the Government Pharmaceutical Organization has continuously developed using hatching egg technology to produce the NDV-HXP-S COVID vaccine in collaboration with PATH and the Faculty of Tropical Medicine, Mahidol University by Professor Emeritus Dr. Punnee Pitisuttithum. Vaccine Trial Centre has tested this vaccine in Phase 1 and found it to be highly safe, good immunity. This vaccine is currently in Phase 3 clinical studies by the Ministry of Public Health. It can be seen that Professor Emeritus Dr. Punnee Pitisuttithum is a part that helps push the company to continue producing vaccines within the country and hopes for sustainability in the future.
Vaccine Trial Centre, Professor Emeritus Dr. Punnee Pitisuttithum Is the main responsible person and conducts clinical research. The vaccine was found to be safe, effective in stimulating the body’s immune system. The Government Pharmaceutical has brought research results to apply for registration and received permission from the Food and Drug Administration (FDA) to produce for use in the event of an outbreak in July 2011 (Fluvac) and June 2015 (Fluvac H5), respectively.
For the first time in Thailand Able to develop and produce vaccines (by the Government Pharmaceutical Organization) successfully used in the country in 2 types: the live attenuated influenza vaccine 2009 (H1N1) or Fluvac, intended to support the outbreak. and the live H5N2 avian influenza vaccine or Fluvac H5
Using chicken egg incubation technology. The objective is to prepare for the outbreak. Both of these vaccines have passed phase 1 and 2 of human trials (Clinical Trial Phase I and II).
Both types of live attenuated vaccines are administered through nasal spray and are supplied as a liquid containing one dose (0.5 mL). This approach helps in lowering the healthcare costs for the country, enhancing accessibility of the vaccine for people. It ensures vaccine security within the nation, ensuring availability during outbreaks. Moreover, it serves as a sanctuary for neighboring countries and the broader Asian region, including nations experiencing outbreaks. This strategy ensures global vaccine reserves and sufficient availability worldwide.
Influenza vaccine project To support the pandemic (Pandemic Influenza Vaccine) against influenza 2009 (H1N1), this was selected as “1 of 8 works that give pride to Thai people” from the Public Relations Office. Office of the Permanent Secretary, Ministry of Public Health, year 2009
Photo news: Interview with Professor Emeritus Dr. Punnee Pitisuttithum in the Daily News newspaper, issue dated 30 July 2017